Used primarily in pharmaceutical research as a key intermediate in the synthesis of targeted protein degraders, particularly cereblon E3 ligase modulators. Its structure enables selective binding to cereblon, making it valuable in developing PROTACs (proteolysis-targeting chimeras) for cancer therapy and inflammatory diseases. The compound's ability to recruit specific proteins for ubiquitination and subsequent degradation allows for precise control over disease-related protein levels. It is also explored in the design of molecular glues that enhance interactions between E3 ligase and target proteins. Due to its bromo and fluoro substituents, it offers favorable reactivity and binding properties for further chemical modifications in drug discovery programs.